---
title: A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)
nct_id: NCT00907738
overall_status: COMPLETED
phase: PHASE2
sponsor: Merck Sharp & Dohme LLC
study_type: INTERVENTIONAL
primary_condition: Advanced Cancer
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00907738.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00907738"
ct_last_update_post_date: 2015-05-21
last_seen_at: "2026-05-12T07:30:58.685Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)

**Official Title:** A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers

**NCT ID:** [NCT00907738](https://clinicaltrials.gov/study/NCT00907738)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 27
- **Lead Sponsor:** Merck Sharp & Dohme LLC
- **Conditions:** Advanced Cancer
- **Start Date:** 2005-08
- **Completion Date:** 2010-06
- **CT.gov Last Update:** 2015-05-21

## Brief Summary

This study will evaluate the safety and tolerability of continuing vorinostat (MK-0683) dosing in cancer patients previously enrolled in one of five base studies (MK-0683-001, MK-0683-006, MK-0683-008, MK-0683-012, or MK-0683-013) who have shown benefit from receiving this drug.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patient participated in one of the five vorinostat base protocols, has not shown tumor progression on that study, and has tolerated the study drug
* Patient did not withdraw from the base protocol
* Patient agrees to practice effective birth control during the study

Exclusion Criteria:

* Patient is receiving other standard and/or investigational anticancer therapy
* Patient has any condition or disease that would interfere with compliance or pose addition risk in administering the study drug
```

## Arms

- **Vorinostat** (EXPERIMENTAL)

## Interventions

- **vorinostat** (DRUG) — All patients will receive vorinostat at the same dose and schedule as they received in the base protocol until disease progression or unacceptable toxicity.

## Primary Outcomes

- **Percent of Participants With a Serious Drug-related Adverse Event (AE)** _(time frame: From the first dose of study drug until the patient experiences disease progression, withdraws consent, or develops unacceptable toxicity (from Day 1 up to 4 years and 9 months))_ — A serious adverse event (SAE) was any AE occurring at any dose that resulted in death, was life-threatening, resulted in a persistent or significant disability/incapacity, resulted in or prolonged an existing inpatient hospitalization, was a congenital anomaly/birth defect, was a cancer, or was an overdose.

A drug-related SAE was one that was thought to be possibly, probably, or definitely related to the study drug.

## Recent Field Changes (last 30 days)

- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00907738.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00907738*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*